

■(6) JP6267792 (dosage)

■Patent owner: Amgen

[Claim 1] A pharmaceutical composition for lowering serum LDL cholesterol in a patient having dysfunction of LDL receptor activity comprising an anti-PCSK9 antibody, wherein the anti-PCSK9 antibody comprises a light chain complementarity determining region (CDR) 1 of the CDRL1 sequence in SEQ ID NO:23, a CDRL2 of the CDRL2 sequence in SEQ ID NO:23, and a CDRL3 of the CDRL3 sequence in SEQ ID NO:23, and a heavy chain complementarity determining region (CDR) 1 of the CDRH1 sequence in SEQ ID NO: 49, a CDRH2 of the CDRH2 sequence in SEQ ID NO: 49, and a CDRH3 of the CDRH3 sequence in SEQ ID NO: 49, and the anti-PCSK9 antibody is administered to the patient at a dose of 420 mg every 2 weeks, thereby lowering the serum LDL cholesterol level by at least 10%.